See more : Intec Capital Limited (INTECCAP.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Inhibrx Biosciences, Inc. (INBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inhibrx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- HolidayCheck Group AG (0G8Z.L) Income Statement Analysis – Financial Results
- Rubius Therapeutics, Inc. (RUBY) Income Statement Analysis – Financial Results
- Quickstep Holdings Limited (QHL.AX) Income Statement Analysis – Financial Results
- Reinsurance Group of America, Incorporated (RZA) Income Statement Analysis – Financial Results
- AS Tallink Grupp (TALLINK.HE) Income Statement Analysis – Financial Results
Inhibrx Biosciences, Inc. (INBX)
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.80M | 2.18M | 7.13M | 12.81M | 9.09M | 7.50M | 7.95M | 6.67M |
| Cost of Revenue | 1.19M | 2.85M | 2.69M | 73.50M | 47.91M | 33.45M | 25.51M | 16.99M |
| Gross Profit | 609.00K | -668.00K | 4.44M | -60.69M | -38.81M | -25.95M | -17.56M | -10.33M |
| Gross Profit Ratio | 33.83% | -30.67% | 62.27% | -473.82% | -426.86% | -346.05% | -220.88% | -154.87% |
| Research & Development | 191.64M | 110.19M | 71.44M | 73.50M | 47.91M | 33.45M | 25.51M | 16.99M |
| General & Administrative | 29.38M | 21.12M | 12.36M | 6.84M | 9.02M | 4.65M | 2.61M | 1.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -253.00K |
| SG&A | 29.38M | 21.12M | 12.36M | 6.84M | 9.02M | 4.65M | 2.61M | 1.57M |
| Other Expenses | 0.00 | -14.00K | -106.00K | -80.00K | -4.12M | 68.00K | 24.00K | 0.00 |
| Operating Expenses | 219.83M | 131.30M | 83.69M | 80.25M | 52.81M | 37.01M | 27.68M | 18.56M |
| Cost & Expenses | 221.02M | 131.30M | 83.69M | 80.25M | 52.81M | 37.01M | 27.68M | 18.81M |
| Interest Income | 11.92M | 16.11M | 5.22M | 10.82M | 5.72M | 0.00 | 0.00 | 759.00K |
| Interest Expense | 31.84M | 16.11M | 5.22M | 10.82M | 5.72M | 1.48M | 2.13M | 0.00 |
| Depreciation & Amortization | 1.19M | 1.23M | 2.69M | 2.39M | 2.52M | 676.00K | 399.00K | 253.00K |
| EBITDA | -206.69M | -125.82M | -76.56M | -67.44M | -42.60M | -28.77M | -19.31M | -11.89M |
| EBITDA Ratio | -11,482.94% | -5,928.24% | -1,074.58% | -526.57% | -468.54% | -383.59% | -242.83% | -178.39% |
| Operating Income | -219.22M | -129.12M | -76.56M | -67.44M | -43.71M | -29.51M | -19.73M | -12.15M |
| Operating Income Ratio | -12,178.94% | -5,928.24% | -1,074.58% | -526.57% | -480.74% | -393.51% | -248.15% | -182.18% |
| Total Other Income/Expenses | -20.50M | -29.90M | -5.20M | -8.19M | -6.79M | -1.41M | -2.10M | -739.00K |
| Income Before Tax | -239.72M | -145.22M | -81.77M | -75.63M | -50.50M | -30.93M | -21.83M | -12.89M |
| Income Before Tax Ratio | -13,318.00% | -6,667.72% | -1,147.59% | -590.52% | -555.39% | -412.33% | -274.59% | -193.27% |
| Income Tax Expense | 3.00K | 3.00K | 2.00K | 3.00K | 898.00K | 96.00K | 250.00K | -4.62M |
| Net Income | -241.36M | -145.23M | -81.77M | -75.64M | -51.40M | -31.16M | -19.44M | -8.27M |
| Net Income Ratio | -13,408.94% | -6,667.86% | -1,147.62% | -590.54% | -565.27% | -415.51% | -244.55% | -124.03% |
| EPS | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| EPS Diluted | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| Weighted Avg Shares Out | 47.13M | 40.11M | 38.01M | 25.26M | 36.55M | 27.08M | 28.79M | 36.55M |
| Weighted Avg Shares Out (Dil) | 47.13M | 40.11M | 38.01M | 25.26M | 36.55M | 27.08M | 28.79M | 36.55M |
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former...
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of...
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory...
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second...
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101,...
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx...
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms...
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company...
Source: https://incomestatements.info
Category: Stock Reports